PowerPoint Presentation

[Virtual Presenter] Rexulti® is a pioneering adjunctive therapy for Major Depressive Disorder. It is an innovative advancement in treatment offering an addition to existing options that may have the potential to enhance patient outcomes and quality of life. Rexulti® is a vital development for individuals coping with Major Depressive Disorder. It presents a novel choice for those seeking adjunctive treatment and the opportunity to enhance results and quality of life. With Rexulti® patients can investigate new possibilities and get the opportunity to take control of their health..

[Audio] rexulti is an FDA-approved adjunctive therapy for major depressive disorder designed to improve symptoms and expand treatment options. It is administered orally in 2 milligrams tablets and other dosage strengths either with or without food once daily. However certain warnings should be taken into consideration. Studies have revealed an increase in suicidal thoughts and behaviors among individuals 24 years of age and younger compared to placebo in short-term studies. It is advised that all patients using rexulti be monitored for clinical worsening and the emergence of suicidal thoughts and behaviors. Moreover elderly patients with dementia-related psychosis have an increased risk of death (1.6 to 1.7 times) compared to placebo when using this treatment and therefore it is not approved for use in such patients..

[Audio] The STAR*D study showed that 49% of patients responded positively to monotherapy as the first step of antidepressant therapy while subsequent therapy steps exhibited a declining response rate of 29% 17% and 16% respectively. Each treatment step lasted for about 12 to 14 weeks therefore it is evident that getting the right treatment rapidly is critical for a successful recovery. rexulti® (brexpiprazole) may be the key to open new possibilities for those suffering from Major Depressive Disorder so that they can access the help they need as soon as possible..

[Audio] Physicians often have the difficult task of finding the most suitable treatment for patients suffering from major depressive disorder when previous medications did not show results. rexulti® (brexpiprazole) is now offered potentially giving physicians a chance to provide adjunct therapy to their patients. rexulti® (brexpiprazole) may be a suitable solution for those in quest of new treatment for Major Depressive Disorder so that they can give their patients the best care..

[Audio] A 2006 study conducted by Rush AJ et al found that when switching from a primary S-S-R-I to another type of antidepressant on average 28.2% of patients achieved a response. This number varied depending on the type of antidepressant with 26.1% achieving a response following a switch to an N-D-R-I 27% to a S-S-R-I and 26.7% to an S-N-R-I-. This study showed the potential of switching from a S-S-R-I to another type of antidepressant to open up possibilities for patients seeking a more effective treatment response..

[Audio] Major depressive disorder can be treated more effectively with adjunctive therapy which allows for the highest level of efficiency with minimal side effects. Increasing the dosage of medication can reduce side effects but lowered doses can help with depression symptoms but may also come with some unwanted side effects. Therefore it is wise to consult with a therapist to determine the best way to get the most benefit from treatment and strive for the best possible outcomes..

[Audio] rexulti® (brexpiprazole) is an exciting new treatment for Major Depressive Disorder that gives patients a new option for relief. By adding rexulti® (brexpiprazole) to existing treatments the potential is there to help patients in ways not seen before. It’s a therapy with great potential offering the possibility of greater relief and improved remission rates..

[Audio] Brexpiprazole the active ingredient in Rexulti was designed to bind to multiple receptors which gives it a unique approach to treating Major Depressive Disorder. By combining partial agonist activity at serotonin 5-HT1 ampere and dopamine D2 receptors as well as antagonist activity at serotonin 5-HT2 ampere receptors Rexulti provides a distinct range of binding affinities to provide relief of symptoms associated with MDD..

[Audio] rexulti® (brexpiprazole) is a unique medication for use as an adjunct to antidepressant therapy (A-D-T--) in treating major depressive disorder (M-D-D--) in adults. Its efficacy was demonstrated in two pivotal clinical trials which compared patients randomized to receive rexulti® in combination with A-D-T with those receiving placebo and A-D-T--. Analysis of results at the end of the treatment period showed a greater reduction in M-D-D symptoms in the group receiving rexulti® as measured by the Montgomery-Åsberg Depression Rating Scale than in the placebo group. rexulti® therefore holds promise in providing relief from M-D-D symptoms..

[Audio] A randomized population comparison of patient baseline characteristics and presentation between those receiving A-D-T plus placebo versus A-D-T plus rexulti® revealed differences in age BMI and gender distribution as well as the history of the randomized population. Of those who received A-D-T plus rexulti® 80.6% had one A-D-T failure 17.5% had two A-D-T failures and 1.9% had three A-D-T failures. These findings suggest that rexulti® may be an effective adjunctive therapy for Major Depressive Disorder providing new possibilities for patients..

[Audio] rexulti® is an adjunctive therapy for Major Depressive Disorder that was found to produce a statistically superior reduction in mean madrs score at a 6-week endpoint in Study 11. According to a mixed-model repeated measures analysis comparing the change in madrs score between rexulti® 2 milligrams and placebo results showed that rexulti® was able to produce a reduction in madrs total score of -8.4. As such it is a safe and effective treatment option with the potential to improve outcomes for patients..

[Audio] rexulti® is an F-D-A approved adjunctive therapy for Major Depressive Disorder which can present possible options for patients. In two major studies the most prevalent side effects were akathisia and weight gain in at least 5% of the patients taking rexulti® which was at least twice as much as seen in patients taking placebo. Furthermore 3% of the patients taking rexulti® stopped the treatment due to side effects compared to 1% of those taking placebo. It is important to consult your doctor for more information about the side effects of rexulti® before beginning treatment..

[Audio] Potential for Major Depressive Disorder patients to experience increased glucose levels is something to bear in mind. Studies which included participants taking rexulti® (brexpiprazole) as adjunctive therapy to their current antidepressant therapy observed an increase in mean fasting glucose levels and shift from normal to high range and from borderline to high range. In the long-term open-label studies 5% of those with normal baseline glucose experienced a shift to high while 25% of those with borderline fasting glucose experienced similar shifts. It is imperative for physicians and patients to be aware of the potential side effects of rexulti®..

[Audio] rexulti® has been studied for its potential as an adjunctive therapy for those with Major Depressive Disorder with studies 1 and 2 demonstrating statistically significant mean changes of negative 2.3 and negative 4 in total cholesterol and H-D-L cholesterol respectively in addition to positive changes in L-D-L cholesterol and triglycerides. These findings suggest that rexulti® may be a beneficial therapy for those with Major Depressive Disorder..

[Audio] Results from two major long-term clinical trials of rexulti® have suggested that alterations to lipid parameters such as total cholesterol HDL and L-D-L cholesterol and triglycerides could take place. Specifically 9% of participants had their total cholesterol levels shift from normal to high while 14% experienced a decrease in their H-D-L cholesterol levels from normal to low. Additionally 17% of those with normal baseline triglycerides showed increases to high and 0.2% shifted to very high..

[Audio] Patients who received rexulti® (brexpiprazole) on top of other treatments for Major Depressive Disorder had a mean weight change of 2.9 kilograms after 26 weeks and 3.1 kilograms after 52 weeks in long-term open-label studies. 4% of studied patients stopped taking it due to weight increase and 30% experienced a 7% or more weight increase. This indicates the potential of rexulti® to give patients more possibilities..

[Audio] rexulti® is an adjunctive therapy for Major Depressive Disorder that can open up possibilities for patients. Administered orally it is recommended to begin with a dose of 0.5 to 1 milligrams taken once daily with or without food. This can be increased up to a maximum of 3 milligrams with the target dosage being 2 milligrams. For those who need assistance adapting to the dosage starting packs containing a 14-day supply are also available. Additionally dose adjustment may be necessary depending on other medications being taken. rexulti® may offer considerable benefit as an adjunctive treatment for those affected by Major Depressive Disorder..

[Audio] rexulti® (brexpiprazole) is an adjunctive therapy indicated for adults with major depressive disorder. While safety efficacy and tolerability of the combination of rexulti® and antidepressants have been clinically studied potential risks should be noted and patients should be monitored closely for clinical worsening or the emergence of suicidal thoughts and behaviors particularly during the initial few months of therapy and at dosage changes..

[Audio] Rexulti has been approved as an adjunctive therapy for Major Depressive Disorder offering patients a potential new option in their treatment. However it is important to be aware of the risks especially for elderly patients with dementia-related psychosis. Such patients should not take Rexulti as it has been found to increase risk of death compared to taking a placebo. For detailed safety information and indications please refer to the full prescribing information..

[Audio] rexulti® is an FDA-approved adjunctive therapy for major depressive disorder that provides an additional treatment option to help those living with depression. Its active ingredient brexpiprazole works to decrease the severity of depressive symptoms. However it is important to be aware of the potential risks associated with the drug. Contraindications include known hypersensitivity reactions such as facial swelling urticaria and anaphylaxis. rexulti® has also been associated with cerebrovascular adverse events including stroke. Additionally Neuroleptic Malignant Syndrome a potentially fatal complex may occur with the administration of the drug. Therefore doctors should be made aware of any medical problems before prescribing rexulti®..

[Audio] rexulti® is a medication for those with Major Depressive Disorder that may help reduce its symptoms. It is an adjunctive therapy meaning it should be used with prescribed antidepressants. It is important to be aware of the associated risks of using rexulti® which include TD a potentially irreversible syndrome and abnormal changes in metabolic functions such as hyperglycemia or diabetes mellitus. In order to be safe it is essential for patients to be monitored regularly and to be aware of the side effects..

[Audio] rexulti is an adjunctive therapy for Major Depressive Disorder which may help with symptom management. Prior to using this medication it is important to understand the safety information about potential side effects such as Hyperglycemia Dyslipidemia Weight Gain and Leukopenia Neutropenia and Agranulocytosis. The prescribing information of rexulti should be read and discussed with healthcare professionals..

[Audio] rexulti® (brexpiprazole) is an adjunctive therapy approved for Major Depressive Disorder. It may help with certain signs and symptoms of the disorder but it is important to be aware of potential side effects such as orthostatic hypotension and an increased risk of seizures. Before beginning this medication a healthcare provider should be consulted to discuss the full range of side effects and to determine if rexulti® (brexpiprazole) is an appropriate therapy..

[Audio] When considering a potential adjunctive option for those struggling with major depressive disorder rexulti® (brexpiprazole) should be taken into account. However potential dysphagia cognitive and motor impairment alcohol use and interactions with other medications must also be considered. Therefore it is important to consult the full prescribing information to understand the benefits and risks of rexulti® (brexpiprazole)..